Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an announcement.
IRLAB Therapeutics AB announced a presentation and webcast for their Q2 2025 interim report, scheduled for August 27, 2025. The report will be discussed by key executives, providing insights into the company’s financial performance and ongoing projects, potentially impacting stakeholder perceptions and industry positioning.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing innovative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing several compounds through clinical trials, including Mesdopetam for levodopa-induced dyskinesias and Pirepemat for reducing fall frequency in Parkinson’s patients. Their research is driven by a proprietary systems biology-based platform, and they are listed on Nasdaq Stockholm.
Average Trading Volume: 120,144
Technical Sentiment Signal: Sell
Current Market Cap: SEK260.9M
For an in-depth examination of IRLAB.A stock, go to TipRanks’ Overview page.